Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
The concept of IgG4-related diseases originated in Japan about 15 years ago. The concept, diagnostic criteria and treatment of the IgG4-related diseases have been emerging. At this session, two faculty experts will present seminars on updates in IgG4-related disease. Talks will explore IL-6, which was first reported in Japan in 1986, and the anti-IL-6 receptor antibody tocilizumab, which was initially approved for the treatment of rheumatoid arthritis in Japan. Tocilizumab's application has been expanded to other refractory diseases, including large-vessel arteritis and adult-onset Still's disease. This session will review differential diagnosis of IGg4-related diseases, optimal therapeutic strategies, and the efficacy and safety of IL-6 inhibition therapy in this patient population, as well as those with large-vessel vasculitis and adult-onset Still's disease.